TerminatedPhase 1

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Stopped: Too challenging to recruit appropriate participants at an acceptable speed.

Germany109 participantsStarted 2015-07-16

Plain-language summary

The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. * Male or female aged 18-65 years (both inclusive) * T2DM diagnosis Exclusion Criteria: * Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics * Use of GLP-1 mimetics or DPP-IV inhibitors * Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%

What they're measuring

Change from baseline (week -1) in the number of reflux episodes

Timeframe: 24 hours after 10 weeks of treatment

Trial details

NCT IDNCT02231658

SponsorProfil Institut für Stoffwechselforschung GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-07-23

View on ClinicalTrials.gov More Diabetes Mellitus trials